Ibrutinib Results Suggest Potential To Shake Up CLL Market
Executive Summary
Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.
You may also be interested in...
Novel CLL Drugs Jockey For Position In Tomorrow’s Revolutionized Market
Gilead’s idelalisib, Roche’s Gazyva and Infinity’s IPI-145 are among a wave of new drugs promising to transform the way the disease is treated across lines of therapy.
Ibrutinib’s Clean Label For Mantle Cell Leukemia Bodes Well For CLL Claim
Pharmacyclics/Janssen’s Imbruvica carries a high list price, but also patient support.
Sizing Up The Competition In BTK Inhibition
Celgene’s latest Phase I dose-ranging data for the BTK inhibitor CC-292 show better response rates than before. The BTK target has become highly attractive, yet the competitive landscape for this particular class still looks sparse, with four drugs in the clinic and two slated for INDs in 2014.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: